Syndax Pharmaceuticals
Waltham
About Syndax Pharmaceuticals
Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor. Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $10K – $50K
- Total funding: $1.1B
- Funding stage: IPO
- Last round: Post-IPO Debt (Nov 2024)
- Ticker: nasdaq:SNDX
- Website: syndax.com
- Phone: (185) 879-2799
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/syndax-pharmaceuticals-60158 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.